LEUKEMIA, published by SpringerNature, is a premier journal in the field of hematology and oncology, with ISSN 0887-6924 and E-ISSN 1476-5551. Established in 1987, this esteemed publication serves as a critical platform for disseminating groundbreaking research and comprehensive reviews on the pathophysiology, diagnosis, and treatment of leukemia and related hematological disorders. With a distinguished impact, it holds a top-tier status in several categories, including Q1 rankings in Anesthesiology and Pain Medicine, Cancer Research, Hematology, and Oncology for 2023. The journal is globally recognized for its rigorous peer-review process and is highly regarded among academia, evidenced by its impressive Scopus rankings—7th in Hematology and 24th in Oncology. Researchers, clinicians, and students alike will benefit from the rich content that this journal offers, making it an invaluable resource in the fight against leukemia. The main objective of LEUKEMIA is to advance knowledge and encourage further innovations within the field, ensuring that vital insights reach practitioners and researchers around the world.

PLATELETS is a distinguished journal published by Taylor & Francis Inc that has been at the forefront of research in the fields of hematology and medicine since its inception in 1990. With an ISSN of 0953-7104 and an E-ISSN of 1369-1635, this journal boasts a solid reputation, as reflected by its Q2 ranking in both Hematology and Miscellaneous Medicine categories in 2023. PLATELETS serves as an essential platform for disseminating pioneering research, reviews, and case studies related to platelet biology, thrombosis, hemostasis, and their clinical implications. Although not an open-access publication, it is indexed in reputable databases, ensuring visibility and citation of quality contributions. Researchers, clinicians, and students alike will find valuable insights that may inform their work and enhance their understanding of the crucial role of platelets in health and disease. This journal's commitment to advancing knowledge and fostering innovation makes it a pivotal resource in the academic community.

THROMBOSIS RESEARCH is a leading peer-reviewed journal in the field of hematology, published by PERGAMON-ELSEVIER SCIENCE LTD. With an impressive impact factor and ranked within the top 10 of 137 in its category according to Scopus, this journal provides a critical platform for the dissemination of innovative research related to thrombosis and hemostasis. Established in 1972, THROMBOSIS RESEARCH has been at the forefront of scholarly communication, addressing key issues, findings, and advancements over more than five decades. Recognized for its high-quality content, the journal is categorized in the Q1 quartile for 2023, reflecting its influence and relevance within the scientific community. Researchers, medical professionals, and students engaged in the study of blood disorders will find valuable insights and the latest discoveries within its pages. Although currently not an open-access publication, THROMBOSIS RESEARCH remains accessible to a wide audience through institutional subscriptions, ensuring that vital research continues to inform and enhance clinical practices around the globe.

Thrombosis Journal is a pioneering open-access publication offering critical insights into the field of hematology, contributing significantly to the understanding of thrombotic diseases. Published by BMC since its inception in 2003, this journal stands out with its commitment to accessibility and dissemination of research, ensuring that valuable findings are readily available to the global scientific community. With an impressive Q2 ranking in the Hematology category as of 2023, the journal boasts a notable presence in the Scopus rankings, positioned at Rank #73/137 in its field. Researchers, healthcare professionals, and students can benefit from a rich array of articles that encompass clinical studies, reviews, and innovative methodologies, all aimed at advancing knowledge and fostering collaboration in the field. The journal is headquartered in the United Kingdom, and its open-access model has enabled a diversity of perspectives and research innovations to flourish, solidifying Thrombosis Journal as an essential resource for those dedicated to combating thrombotic disorders.

THROMBOSIS AND HAEMOSTASIS is a prestigious journal published by GEORG THIEME VERLAG KG, dedicated to advanced research in the field of hematology. With an esteemed Impact Factor and recognized as Q1 in its category for 2023, the journal is regarded for its pivotal role in disseminating significant findings that contribute to our understanding of thrombosis and hemostasis. Since its inception in 1976, this journal has continuously published cutting-edge studies and reviews, making it a vital resource for researchers, healthcare professionals, and students alike. The journal’s commitment to high-quality research is reflected in its impressive Scopus Ranking of #18 out of 137 in Medicine - Hematology, placing it in the 87th percentile among its peers. Although not currently open access, THROMBOSIS AND HAEMOSTASIS remains an authoritative source for exploring novel therapeutic strategies and the latest scientific advancements in the field. Based in Stuttgart, Germany, this journal serves as a critical platform for sharing knowledge and fostering collaboration within the global hematology community.

HEMOGLOBIN, a prominent journal published by Taylor & Francis Ltd, serves as a vital resource in the fields of Biochemistry, Clinical Biochemistry, Genetics, and Hematology. Established in 1976, the journal provides a platform for innovative research and review articles that explore the complexities of hemoglobin pathology and related disorders, making significant contributions to our understanding of hematological diseases. With an ISSN of 0363-0269 and an E-ISSN of 1532-432X, HEMOGLOBIN has garnered attention within the academic community, reflected in its category quartiles for 2023, which rank it in the Q3 and Q4 levels across relevant medical and biochemistry categories. Although it operates on a subscription basis rather than as an open-access journal, it remains influential, providing critical insights to researchers, professionals, and students aiming to address the current challenges in blood research and related fields. The journal not only emphasizes high-quality scientific analyses but also seeks to foster collaboration and dialogue among academia and clinical practitioners, ultimately advancing the frontier of knowledge in hemoglobin and hematological research.

Revista de Gastroenterologia de Mexico, published by Elsevier, serves as a vital platform for advancing knowledge in the field of gastroenterology. Established in Mexico, this esteemed journal boasts an open access format since 2012, promoting widespread dissemination of research findings and enhancing access for healthcare professionals and researchers worldwide. With its impact factor reflecting a growing recognition in the academic community, the journal is currently ranked in the Q3 category for Gastroenterology, indicating its relevance and contribution to the field. Spanning decades of publication history from 1947 to the present, it offers a wealth of medical insights and serves as a critical resource for those engaged in clinical practice and research. The journal aims to publish high-quality original research, reviews, and clinical studies, making it an essential resource for professionals seeking to stay at the forefront of gastroenterological advancements. Located at Radarweg 29, 1043 NX Amsterdam, Netherlands, the journal embraces a holistic approach to gastroenterology, encouraging contributions that enrich the understanding and treatment of gastrointestinal disorders.

BLOOD REVIEWS is a highly regarded journal published by Churchill Livingstone, specializing in the fields of Hematology and Oncology. With an impressive Q1 ranking in both disciplines and placing in the top 10% of its peer categories according to Scopus metrics, it provides an essential platform for the dissemination of cutting-edge research and reviews pertaining to blood disorders and cancer treatment. Since its inception in 1987 and continuing through 2024, the journal has established itself as a cornerstone for healthcare professionals, researchers, and students who seek to advance their understanding of hematologic and oncologic topics. While not an open-access journal, BLOOD REVIEWS retains a reputation for delivering high-quality, peer-reviewed articles that foster dialogue and innovation within the scientific community. For those in the United States and beyond, the journal serves as a vital resource, housed at the Journal Production Department in Edinburgh, Scotland, ensuring accessibility and a global reach in its critical academic contributions.

BLOOD, published by the American Society of Hematology, is a premier peer-reviewed journal in the fields of Biochemistry, Cell Biology, Hematology, and Immunology. With an impressive impact factor and ranking in the top quartiles (Q1) across multiple disciplines, BLOOD is essential reading for researchers and professionals seeking to stay updated on the latest advancements in hematology and related fields. The journal has been a cornerstone of hematological research since its inception in 1946, providing a platform for rigorous scientific inquiry and discourse. Its commitment to publishing high-quality original research, comprehensive reviews, and insightful editorials makes it a vital resource for students, practitioners, and scientists alike. By offering exceptional access to influential publications, BLOOD continues to shape the future of hematology and enhance understanding of blood-related disorders, marking its vital role in advancing both basic and clinical research.

NATURE REVIEWS CANCER, a premier journal published by NATURE PORTFOLIO, stands as a cornerstone in the field of oncology, focusing on delivering high-quality, comprehensive reviews that shape our understanding of cancer biology, prevention, and treatment. With an impressive impact in the academic community, it ranks Q1 in both Cancer Research and Oncology categories as of 2023, further denoted by a remarkable Scopus ranking as the top journal in Cancer Research and second in Oncology. This ensures that published articles not only set the standard for scientific excellence but also drive significant advancements in cancer research methodologies and practices. The journal's targeted audience, including researchers, practitioners, and students, will greatly benefit from its insightful analyses and interdisciplinary approach. While it operates under a traditional subscription model, the rich content and vast expertise presented in its articles foster a global dialogue on cancer-related issues, making it an essential resource for anyone dedicated to the advancement of cancer science.